CN113412124A - Baff-r双特异性t细胞衔接子抗体 - Google Patents

Baff-r双特异性t细胞衔接子抗体 Download PDF

Info

Publication number
CN113412124A
CN113412124A CN201980089634.XA CN201980089634A CN113412124A CN 113412124 A CN113412124 A CN 113412124A CN 201980089634 A CN201980089634 A CN 201980089634A CN 113412124 A CN113412124 A CN 113412124A
Authority
CN
China
Prior art keywords
seq
chain variable
variable domain
recombinant protein
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089634.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·秦
L·W·郭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Priority to CN202511607565.0A priority Critical patent/CN121405815A/zh
Publication of CN113412124A publication Critical patent/CN113412124A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980089634.XA 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体 Pending CN113412124A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511607565.0A CN121405815A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782317P 2018-12-19 2018-12-19
US62/782,317 2018-12-19
PCT/US2019/067563 WO2020132291A1 (en) 2018-12-19 2019-12-19 Baff-r bispecific t-cell engager antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511607565.0A Division CN121405815A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体

Publications (1)

Publication Number Publication Date
CN113412124A true CN113412124A (zh) 2021-09-17

Family

ID=71098268

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980089634.XA Pending CN113412124A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体
CN202511607565.0A Pending CN121405815A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511607565.0A Pending CN121405815A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体

Country Status (8)

Country Link
US (2) US20200199232A1 (https=)
EP (1) EP3897720A4 (https=)
JP (2) JP2022515152A (https=)
KR (1) KR20210104816A (https=)
CN (2) CN113412124A (https=)
AU (1) AU2019404282A1 (https=)
CA (1) CA3123599A1 (https=)
WO (1) WO2020132291A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CA3261672A1 (en) * 2022-07-19 2024-01-25 Novartis Ag TREATMENT OF AIHA WITH BAFF OR BAFF RECEPTOR INHIBITOR ANTIBODIES
AU2024227909A1 (en) * 2023-02-28 2025-08-14 Mayo Foundation For Medical Education And Research Molecules that bind to b-cell activating factor receptor polypeptides
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
CN104780940A (zh) * 2012-11-06 2015-07-15 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
WO2016016415A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
US20170218077A1 (en) * 2016-02-03 2017-08-03 Amgen Research (Munich) Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
WO2017214170A2 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r antibodies and uses thereof
WO2017214167A1 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
US20180057593A1 (en) * 2015-05-01 2018-03-01 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
US20180117152A1 (en) * 2015-06-16 2018-05-03 Genentech, Inc. Anti-cd3 antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2216342B1 (en) * 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
US10072088B2 (en) * 2015-08-17 2018-09-11 Janssen Pharmaceutica, Nv Anti-BCMA antibodies and uses thereof
KR20210129125A (ko) * 2019-02-20 2021-10-27 시티 오브 호프 Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104780940A (zh) * 2012-11-06 2015-07-15 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2016016415A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
US20180057593A1 (en) * 2015-05-01 2018-03-01 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
US20180117152A1 (en) * 2015-06-16 2018-05-03 Genentech, Inc. Anti-cd3 antibodies and methods of use
US20170218077A1 (en) * 2016-02-03 2017-08-03 Amgen Research (Munich) Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
WO2017214170A2 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r antibodies and uses thereof
WO2017214167A1 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRIEDERIKE BRAIG ET AL.: "Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking", 《BLOOD》, vol. 129, no. 1, pages 100, XP086676899, DOI: 10.1182/blood-2016-05-718395 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用

Also Published As

Publication number Publication date
CA3123599A1 (en) 2020-06-25
WO2020132291A1 (en) 2020-06-25
US20200199232A1 (en) 2020-06-25
AU2019404282A1 (en) 2021-07-01
KR20210104816A (ko) 2021-08-25
EP3897720A4 (en) 2022-12-07
CN121405815A (zh) 2026-01-27
EP3897720A1 (en) 2021-10-27
JP2022515152A (ja) 2022-02-17
JP2025032075A (ja) 2025-03-11
US20220056132A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP7391510B2 (ja) ヒト化抗ｃｄ７３抗体
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
CN113412124A (zh) Baff-r双特异性t细胞衔接子抗体
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
JP7275446B2 (ja) Ｂａｆｆ－ｒ抗体及びその使用
JP7070932B2 (ja) Ｂａｆｆ－ｒ標的化キメラ抗原受容体修飾ｔ細胞及びその使用
CN116077647B (zh) 喹啉衍生物与抗体的药物组合
US20200392239A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
BR112020016944A2 (pt) Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
CN113474362A (zh) 对cd44特异性的抗体
KR20230010221A (ko) 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도
WO2021115303A1 (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
TW201916890A (zh) 抗ｐｄ－１抗體和抗ｌａｇ－３抗體聯合在製備治療腫瘤的藥物中的用途
JP2008519028A (ja) Ｂ細胞悪性腫瘍の治療
KR20240072932A (ko) B7-h3에 특이적으로 결합하는 항체
TW202019962A (zh) 標靶CD38及TGF-β的組合療法
WO2024255467A1 (en) Anti-ccr8 antibody and anti-ccr8/ctla4 bispecific antibody
CN106963950B (zh) 用于治疗肿瘤的联合用药物
HK40098230A (zh) 针对cd112r的抗体及其用途
HK40060753A (en) Antibodies specific to muc18
HK1240845A (en) Combination medicine for tumor treatment
HK1240845A1 (en) Combination medicine for tumor treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination